Meta-analysis reveals significant therapeutic benefits and high safety for upadacitinib in ankylosing spondylitis, highlighting its promise as an effective targeted therapy.
Through a literature analysis, it reveals that UPA offers significant therapeutic benefits to AS patients with a relatively high safety profile.
No takes yet. Share an insight, caveat, or question.
Yao et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: